目的 探讨活血通络汤联合恩格列净治疗射血分数降低型心力衰竭（HFrEF）患者的疗效，并分析其对中医证候积分、心功能的影响。方法 选取2024年8月～2025年8月于本院诊治的150例HFrEF患者进行回顾性分析，依据治疗方案不同将其分为对照组、观察组，其中采取恩格列净治疗的75例患者作为对照组，采取活血通络汤联合恩格列净治疗的75例患者作为观察组。统计对比两组临床疗效及治疗前后中医证候积分、Lee氏心衰积分、心功能、6 min步行试验（6MWT）、心衰因子[心肌肌钙蛋白I（cTnI）、可溶性人基质裂解素2（sST2）、N末端B型利钠肽原（NT-proBNP）]、血流动力学、炎症因子[白细胞介素-6（IL-6）、C反应蛋白（CRP）、白细胞介素-1β（IL-1β）、正五聚蛋白-3（PTX-3）]、氧化应激指标[谷胱甘肽过氧化物酶-3（GPX-3）、丙二醛（MDA）、超氧化物歧化酶（SOD）、脂质过氧化物（LPO）、总抗氧化能力]。比较两组不良反应与再住院率。结果 观察组总有效率高于对照组（P＜0.05）；观察组治疗后中医证候积分、Lee氏心衰积分低于对照组（P＜0.05）；观察组治疗后LVEDD、LVESD、LVEDV、LVESV及血清cTnI、sST2、NT-proBNP水平低于对照组，LVEF、6MWT高于对照组（P＜0.05）；观察组治疗后血流动力学改善程度优于对照组（P＜0.05）；治疗后，与对照组比较，观察组血清IL-6、CRP、IL-1β、PTX-3、MDA、LPO水平降低，GPX-3、SOD、总抗氧化能力水平升高（P＜0.05）；观察组再住院率低于对照组（P＜0.05），且两组不良反应比较无明显差异（P＞0.05）。结论 活血通络汤联合恩格列净治疗HFrEF患者，可提高治疗效果，改善临床症状、心功能，调节血流动力学，并可降低炎症反应，抑制氧化应激反应，减少再住院的发生，且具有一定安全性。

Objective To explore the therapeutic effect of Huoxue Tongluo Decoction combined with empagliflozin on patients with heart failure with reduced ejection fraction (HFrEF), and analyze its influence on traditional Chinese medicine syndrome scores and cardiac function. Methods A retrospective analysis was performed on 150 HFrEF patients treated in our hospital from August 2024 to August 2025. The patients were divided into control group and observation group according to different treatment regimens, 75 patients receiving empagliflozin alone constituted the control group, while another 75 cases treated with combined Huoxue Tongluo Decoction and empagliflozin were assigned to the observation group. The clinical efficacy, as well as the traditional Chinese medicine syndrome scores, Lee heart failure score, cardiac function 6-minute walk test (6MWT), heart failure factors [cardiac troponin I (cTnI), soluble suppression of tumorigenicity 2 (sST2) and N-terminal pro-B-type natriuretic peptide (NT-proBNP)], hemodynamic parameters, inflammatory factors [interleukin-6 (IL-6), C-reactive protein (CRP), interleukin-1β (IL-1β) and pentraxin-3 (PTX-3)], oxidative stress indexes [glutathione peroxidase-3 (GPX-3), malondialdehyde (MDA), superoxide dismutase (SOD), lipid peroxide (LPO) and total antioxidant capacity] before and after treatment were compared between the two groups. Adverse reactions and readmission rate were also compared. Results The total effective rate of observation group was higher than that of control group (P<0.05). After treatment, traditional Chinese medicine syndrome scores and Lee heart failure score in observation group were lower (P<0.05). LVEDD, LVESD, LVEDV, LVESD and serum levels of cTnI, sST2, NT-proBNP decreased, while LVEF and 6MWT increased in observation group (P<0.05). The improvement of hemodynamics in observation group was superior to control group after treatment (P<0.05). After treatment, serum levels of IL-6, CRP, IL-1β, PTX-3, MDA and LPO were decreased, while GPX-3, SOD and total antioxidant capacity were increased in observation group compared with control group (P<0.05). The readmission rate was lower in observation group (P<0.05). No significant difference was found in adverse reactions between the two groups (P>0.05). Conclusion Huoxue Tongluo Decoction combined with empagliflozin can elevate therapeutic efficacy, relieve clinical symptoms, improve cardiac function and hemodynamic status, reduce inflammatory and oxidative stress responses, and cut down readmission incidence with favorable safety in HFrEF patients.

目的 探讨活血通络汤联合恩格列净治疗射血分数降低型心力衰竭（HFrEF）患者的疗效，并分析其对中医证候积分、心功能的影响。方法 选取2024年8月～2025年8月于本院诊治的150例HFrEF患者进行回顾性分析，依据治疗方案不同将其分为对照组、观察组，其中采取恩格列净治疗的75例患者作为对照组，采取活血通络汤联合恩格列净治疗的75例患者作为观察组。统计对比两组临床疗效及治疗前后中医证候积分、Lee氏心衰积分、心功能、6 min步行试验（6MWT）、心衰因子[心肌肌钙蛋白I（cTnI）、可溶性人基质裂解素2（sST2）、N末端B型利钠肽原（NT-proBNP）]、血流动力学、炎症因子[白细胞介素-6（IL-6）、C反应蛋白（CRP）、白细胞介素-1β（IL-1β）、正五聚蛋白-3（PTX-3）]、氧化应激指标[谷胱甘肽过氧化物酶-3（GPX-3）、丙二醛（MDA）、超氧化物歧化酶（SOD）、脂质过氧化物（LPO）、总抗氧化能力]。比较两组不良反应与再住院率。结果 观察组总有效率高于对照组（P＜0.05）；观察组治疗后中医证候积分、Lee氏心衰积分低于对照组（P＜0.05）；观察组治疗后LVEDD、LVESD、LVEDV、LVESV及血清cTnI、sST2、NT-proBNP水平低于对照组，LVEF、6MWT高于对照组（P＜0.05）；观察组治疗后血流动力学改善程度优于对照组（P＜0.05）；治疗后，与对照组比较，观察组血清IL-6、CRP、IL-1β、PTX-3、MDA、LPO水平降低，GPX-3、SOD、总抗氧化能力水平升高（P＜0.05）；观察组再住院率低于对照组（P＜0.05），且两组不良反应比较无明显差异（P＞0.05）。结论 活血通络汤联合恩格列净治疗HFrEF患者，可提高治疗效果，改善临床症状、心功能，调节血流动力学，并可降低炎症反应，抑制氧化应激反应，减少再住院的发生，且具有一定安全性。

Objective To explore the therapeutic effect of Huoxue Tongluo Decoction combined with empagliflozin on patients with heart failure with reduced ejection fraction (HFrEF), and analyze its influence on traditional Chinese medicine syndrome scores and cardiac function. Methods A retrospective analysis was performed on 150 HFrEF patients treated in our hospital from August 2024 to August 2025. The patients were divided into control group and observation group according to different treatment regimens, 75 patients receiving empagliflozin alone constituted the control group, while another 75 cases treated with combined Huoxue Tongluo Decoction and empagliflozin were assigned to the observation group. The clinical efficacy, as well as the traditional Chinese medicine syndrome scores, Lee heart failure score, cardiac function 6-minute walk test (6MWT), heart failure factors [cardiac troponin I (cTnI), soluble suppression of tumorigenicity 2 (sST2) and N-terminal pro-B-type natriuretic peptide (NT-proBNP)], hemodynamic parameters, inflammatory factors [interleukin-6 (IL-6), C-reactive protein (CRP), interleukin-1β (IL-1β) and pentraxin-3 (PTX-3)], oxidative stress indexes [glutathione peroxidase-3 (GPX-3), malondialdehyde (MDA), superoxide dismutase (SOD), lipid peroxide (LPO) and total antioxidant capacity] before and after treatment were compared between the two groups. Adverse reactions and readmission rate were also compared. Results The total effective rate of observation group was higher than that of control group (P<0.05). After treatment, traditional Chinese medicine syndrome scores and Lee heart failure score in observation group were lower (P<0.05). LVEDD, LVESD, LVEDV, LVESD and serum levels of cTnI, sST2, NT-proBNP decreased, while LVEF and 6MWT increased in observation group (P<0.05). The improvement of hemodynamics in observation group was superior to control group after treatment (P<0.05). After treatment, serum levels of IL-6, CRP, IL-1β, PTX-3, MDA and LPO were decreased, while GPX-3, SOD and total antioxidant capacity were increased in observation group compared with control group (P<0.05). The readmission rate was lower in observation group (P<0.05). No significant difference was found in adverse reactions between the two groups (P>0.05). Conclusion Huoxue Tongluo Decoction combined with empagliflozin can elevate therapeutic efficacy, relieve clinical symptoms, improve cardiac function and hemodynamic status, reduce inflammatory and oxidative stress responses, and cut down readmission incidence with favorable safety in HFrEF patients.

目的 分析恩格列净对2型心肾综合征（CRS）患者的治疗效果。方法 研究于2021年10月—2023年10月进行,随机抽取88例2型CRS患者,经计算机程序随机分成对照组（44例,给予常规治疗）、实验组（44例,在常规治疗的同时加用恩格列净）,通过对比两组患者心、肾功能指标来评估疗效,并记录两组患者治疗过程中发生的不良反应。结果 治疗后,实验组LAD、LVED低于对照组,而LVEF高于对照组;实验组血清肌酐、尿酸等肾功能指标水平均低于对照组（均P<0.05）。两组不良反应发生率比较差异无统计学意义（P>0.05）。结论 对于2型CRS患者,恩格列净可促进其心、肾功能的改善,且无过多不良反应,安全性理想,治疗效果可观,值得推广。

Objective To analyze the therapeutic effect of empagliflozin on patients with type 2 cardiorenal syndrome（CRS）．Methods The study was conducted from October 2021 to October 2023,and 88 patients with type 2 CRS were randomly selected and divided into control group（44 cases,receiving conventional treatment）and experimental group（44 cases,receiving conventional treatment combined with englaglitzin）by computer program．The efficacy was evaluated by comparing cardiac and renal function indexes and adverse reactions．Results After treatment,the LAD and LVED of the experimental group were lower than those of the control group,while LVEF was higher than that of the control group．The levels of serum creatinine,uric acid and other renal function indexes in the experimental group were lower than those in the control group after treatment（P<0.05）．There was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）．Conclusions For patients with type 2 CRS,empagliflozin can promote the improvement of cardiac and renal function without many side effects,with ideal safety and considerable therapeutic effect,which is worthy of promotion．